TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive Congress Nearing Final Action On Appropriations, But Potential GRH Cuts Leaves Outlook Unclear September 12, 1986
TCL Archive NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions. December 12, 2003